Publications by authors named "H Camara"
Article Synopsis
- * Study Overview: Conducted from 2014 to 2021 at Kati university hospital, the retrospective study included 68 MTEV cases, with a majority (58.8%) being women. Key findings included high clinical probability scores for DVT and significant occurrences of PE.
- * Conclusion on Gender Disparities: The research concluded that women, particularly postpartum, are more affected by MTEV, with a notable recurrence rate and a mortality rate of
Article Synopsis
- A study was conducted with 941 IBD patients to assess their satisfaction with different adalimumab preparations, including biosimilars and the original brand, Humira.
- The average satisfaction rating was 8.5 out of 10, with the highest satisfaction observed for Humira and its biosimilars like Hulio and Amgevita, where scores were notably above 8.5.
- Injection site reactions were reported by 31.8% of patients, and a portion of those previously treated with another adalimumab had discontinued due to side effects; overall, patient satisfaction remained high despite these issues.
Light is fundamental for biological life, with most mammals possessing light-sensing photoreceptors in various organs. Opsin3 is highly expressed in adipose tissue which has extensive communication with other organs, particularly with the brain through the sympathetic nervous system (SNS). Our study reveals a new light-triggered crosstalk between adipose tissue and the hypothalamus.
View Article and Find Full Text PDFChronic and excessive glucocorticoid (GC) exposure can cause Cushing's syndrome, resulting in fat accumulation in selected body areas. Particularly in the brown adipose tissue (BAT), GC acts negatively, resulting in whitening of the tissue. We hypothesized that dysregulation of microRNAs by GC could be an additional mechanism to explain its negative actions in BAT.
View Article and Find Full Text PDFDifficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment.
United European Gastroenterol J
June 2024
Background: Many patients with inflammatory bowel disease (IBD) have signs or symptoms of active disease despite multiple treatment attempts. This emerging concept is defined as difficult-to-treat IBD.
Aim: The objective of this study was to investigate for the first time the treatment persistence, efficacy and safety of biologics or small molecules used in 4th or 5th line therapy.